Galera Therapeutics, Inc.
GRTX
$0.0239
-$0.0001-0.42%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.70M | 3.44M | 2.78M | 3.09M | 1.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.62M | 3.74M | 4.21M | 4.58M | 5.18M |
| Operating Income | -1.62M | -3.74M | -4.21M | -4.58M | -5.18M |
| Income Before Tax | -4.93M | -5.78M | -4.06M | -4.38M | -5.59M |
| Income Tax Expenses | 0.00 | -203.00K | -- | -- | -- |
| Earnings from Continuing Operations | -4.93M | -5.58M | -4.06M | -4.38M | -5.59M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.93M | -5.58M | -4.06M | -4.38M | -5.59M |
| EBIT | -1.62M | -3.74M | -4.21M | -4.58M | -5.18M |
| EBITDA | -1.62M | -3.74M | -4.20M | -4.57M | -4.96M |
| EPS Basic | -0.09 | -0.10 | -0.07 | -0.08 | -0.10 |
| Normalized Basic EPS | -0.01 | -0.04 | -0.05 | -0.05 | -0.06 |
| EPS Diluted | -0.09 | -0.10 | -0.07 | -0.08 | -0.10 |
| Normalized Diluted EPS | -0.01 | -0.04 | -0.05 | -0.05 | -0.06 |
| Average Basic Shares Outstanding | 55.36M | 54.39M | 54.39M | 54.39M | 54.39M |
| Average Diluted Shares Outstanding | 55.36M | 54.39M | 54.39M | 54.39M | 54.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |